人参皂苷Rb2在大鼠体内的药代动力学行为及代谢产物研究

建立快速高分离度液相色谱-四极杆飞行时间质谱联用方法(RRLC-Q-TOF-MS),分析人参皂苷Rb2在大鼠体内的药代动力学行为,并探索人参皂苷Rb2在大鼠体内的代谢过程.采用Agilent SB-C18色谱柱,流动相A为0.1％甲酸溶液,B为乙腈,流速为0.2 mL/min,进样量为5μL,二元线性梯度洗脱分离,采用电喷雾负离子模式进行质谱检测.方法的检出限(S/N=3)和定量限(S/N=10)分别为0.08 μg/mL和0.1 μg/mL,线性范围为0.10～ 1.26 μg/mL.结果表明,人参皂苷Rb2静脉注射后的体内代谢过程符合二室模型特征,血药浓度半衰期的α相(t1/2α)和β相(t1/2β)分别为(23.58±1.10)和(1306.55±147.23) min.通过对静脉注射人参皂苷Rb2的大鼠尿液和口服后的粪便样本进行分析,发现Rb2的代谢产物为M6,M2(C-Y),F2,C-K.     

HPLC-ELSD测定茜芷胶囊中三七皂苷R1、人参皂苷Rg1及Rb1的含量

利用HPLC-ELSD对茜芷胶囊中的活性成分三七皂苷R1、人参皂苷Rg1和Rb1的含量进行测定.三七皂苷R1、人参皂苷Rg1及Rb1分别在0.13~2.60、0.30~6.00、0.38~7.60μg范围内呈现良好的线性关系,平均回收率分别为98.0%(RSD1.7%),97.1%(RSD1.8%),97.0%(RSD1.5%).该方法简便、准确、重现性好,可用于茜芷胶囊的质量控制.     

液相色谱-质谱联用技术结合多探针底物法研究人参皂苷Rb1的体外代谢

以奥美拉唑、 苯妥英、 卡马西平和非那西丁为检测肝药酶细胞色素P450酶(CYP450)亚型的专属探针药物, 通过原型药物减少量测定法考察药物体外代谢的变化, 评价人参皂苷Rb1对CYP450不同亚型酶的作用. 结果表明, P2C9, P2C19和P3A4实验组与对照组差异不显著, P1A2实验组与对照组差异显著, 表明人参皂苷Rb1能诱导P1A2亚型酶的活性, 促进底物与酶反应, 加快底物的代谢, 而对P2C9, P2C19和P3A4三个亚型酶有弱的诱导或无诱导作用. 根据快速分离液相色谱-质谱联用(RRLC-MS/MS)检测结果推断, 人参皂苷Rb1在CYP450酶中的代谢产物可转化为人参皂苷Rb1氧化产物(Rb1+O)及人参皂苷Rd和F2.     

LC-MS/MS法测定大鼠血浆中人参皂苷Rb1的含量及其药代动力学研究

采用液相色谱-串联质谱法快速、灵敏地测定大鼠血浆中人参皂苷Rb1(GRb1)的含量,并将该方法应用于大鼠口服GRb1后的代谢动力学研究。血浆样品采用96孔板进行液-液萃取后,应用Agilent SB-C18色谱柱(100 mm×2.1 mm,3.5μm)进行分离,以甲醇-0.1%甲酸溶液(体积比为75∶25)为流动相进行洗脱,在正离子模式下对GRb1和内标人参皂苷Rg1(GRg1)进行检测,用于定量的离子反应分别为1131.5→365.1(GRb1),823.3→643.4(GRg1)。人参皂苷Rb1血浆样品测定方法的定量线性范围为1~500 ng/mL,线性相关系数大于0.999,定量下限为1 ng/mL,批内和批间精密度(RSD)小于9.05%,回收率为79.7%~81.0%,基质效应为96.6%~99.3%。大鼠灌胃给予Rb15 mg/kg后,大鼠体内血药浓度到达高峰时间tmax为1.53 h,半衰期t1/2为13.54 h,药时曲线面积AUC0~72为16237.76(ng·h)/mL。该方法快速、高效、灵敏,适用于人参皂苷Rb1的代谢动力学研究。     

尿液代谢组学方法研究人参总皂苷治疗糖尿病心肌病大鼠作用机制

利用基于质谱的代谢组学方法考察了人参总皂苷(TG)治疗糖尿病心肌病(DCM)大鼠的效应机制;建立了糖尿病心肌病大鼠模型,并连续12周口服人参总皂苷,采用快速高分辨液相色谱/四级杆-飞行时间/质谱(RRLC/Q-TOF/MS)技术对糖尿病心肌病模型组(DCM组)和人参总皂苷治疗组(TG组)大鼠尿样的尿液代谢物进行分析,采用主成分分析(PCA)对两组代谢物进行分类,并寻找潜在生物标记物,同时检测心肌病理超微结构、血液生化指标和心肌氧化应激水平。RRLC/Q-TOF/MS检测结果表明,DCM组和TG组大鼠的尿液代谢物谱能得到很好的区分,发现并鉴定了3种生物标记物。TG降低了DCM大鼠心肌超微结构损伤并改善其血脂、血糖及心肌氧化应激水平,代谢组学研究结果表明:作用机制可能是TG对柠檬酸循环、脂肪酸代谢和氧化应激水平的调节作用。     

高效液相色谱-飞行时间质谱联用法分析人参及人参皂苷与山楂配伍过程中的水解行为

利用高效液相色谱-飞行时间质谱联用的方法,分别对人参配伍山楂前后人参皂苷的变化进行分析,同时对人参皂苷Re、Rg1、Rb1、Rd与山楂配伍的水解规律进行系统研究,并与单独煎煮液、仿山楂配伍pH值煎煮液的水解产物进行比较,结果发现人参与山楂配伍后人参皂苷Rg1、Rb1含量明显减少,而人参皂苷Re、Rd、Rg2、Rg3、F2、Rh1含量明显增加,其中人参皂苷Re与山楂配伍后水解产物为人参皂苷20(R)-Rg2、20(S)-Rg2,仿山楂配伍pH值水解产物为人参皂苷20(R)-Rg2、20(S)-Rg2、Rg4、Rg6;人参皂苷Rg1与山楂配伍后水解产物为20(S)-Rh1、20(R)-Rh1,仿山楂pH值水解产物为20(S)-Rh1、20(R)-Rh1、Rh4、Rk3;人参皂苷Rb1与山楂配伍后水解产物为Rd、20(S)-Rg3,仿山楂pH值水解产物为F2、20(S)-Rg3;人参皂苷Rd与山楂配伍后水解产物为F2、20(S)-Rg3、20(R)-Rg3,仿山楂pH值水解产物为20(S)-Rg3、20(R)-Rg3。研究表明,不同人参皂苷和山楂配伍后与仿山楂pH值的水解产物并不相同,人参与山楂配伍改变了人参皂苷成分的种类及含量。本研究为临床方剂中人参与山楂配伍后成分的变化提供物质基础数据。     

基于HPLC-HRMS/MS~n/QqQ技术的人参皂苷Rb_1化学转化产物的结构与途径分析

利用液相色谱-质谱联用技术分析了Keggin型12-磷钨酸化学转化人参皂苷Rb1产物的结构与转化途径.基于高效液相色谱对转化产物的快速分离,利用Q Exactive高分辨质谱的Full MS-AIF模式快速鉴定了产物结构,并利用多级串联质谱进行结构验证.进一步结合人参皂苷异构体在反向C18色谱柱上的相对保留时间,快速分析鉴定出Rb1的10种转化产物为20(S)-Rg3,20(R)-Rg3,20(S)-25-OH-Rg3,20(R)-25-OH-Rg3,25-OH-Rk1,25-OH-Rg5,Rg5,Rk1,(20S,25)-环氧-Rg3和(20R,25)-环氧-Rg3.根据转化产物的结构初步推断了人参皂苷的转化途径:在12-磷钨酸产生的酸性环境中,Rb1主要通过C20位去糖基化、差向异构化和烯烃链的水合、消除及环合反应转化为稀有皂苷.采用三重四极杆质谱的选择反应监测模式准确定量分析了Rb1的转化效率和稀有皂苷20(S)-Rg3,20(R)-Rg3,Rk1和Rg5的产率.定量分析结果显示,与生物转化相比,12-磷钨酸对Rb1有更高的转化效率,反应40 min后转化率达到100%.本文结果表明,HPLC-HRMS/MSn/Qq Q技术是人参皂苷等天然产物结构解析与定量分析的有效方法.     

能量分辨质谱区分与检测人参皂苷同分异构体20(S)-Rf和Rg1

将连续变化的碰撞能量与串联质谱相结合,建立了能量分辨质谱(Energy-resolved mass spectrometry,ERMS)分析方法用以区分和检测人参皂苷同分异构体20(S)-Rf和Rg₁. ERMS将子离子与母离子强度的比值定义为强度分数(Intensity fraction, IF),两个子离子强度的比值定义为强度比(Intensity ratio, IR),并通过IF和IR分别对连续变化的碰撞能量作图建立特征碎片离子的IF和IR曲线.虽然20(S)-Rf和Rg₁的串联质谱图无明显差异,但是多元统计分析结果显示其特征碎片离子[M-Glc-H]^-,[M-2Glc-H]^-和[M-2Glc-C₆H₁₂-H]^-的IF和IR曲线差异显著,有明显的区分边界,可以直接区分20(S)-Rf和Rg₁.进一步利用ERMS实时分析了原人参三醇型皂苷生物转化产物中20(S)-Rf和Rg₁的相对摩尔含...     

人参中皂苷类化合物的HPLC-ESI MS研究

利用高效液相色谱与电喷雾质谱联用技术分析鉴定了人参粗提物中人参皂苷类化合物。实验采用反相C18色谱柱,二元线性梯度洗脱（0．2％的醋酸水溶液和乙腈）,分离并检测了人参中的皂苷类化合物：通过与电喷雾质谱的联用和质谱的源内CID技术获得了其中主要色谱峰相对应化合物的相对分子质量和结构信息。     

In Vivo Metabolism Study of Timosaponin BIII in Rat Using HPLC-QTOF-MS/MS

Timosaponin BIII, as one of the steroid saponins isolated from Anemarrhena asphodeloides Bge., was proved to have many pharmacological activities in recent years and became a natural active compound with good development prospect. In the present study, a simple and rapid method using high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry was developed for the determination of the structures of timosaponin BIII and its metabolites in rats after administrating intragastrically at 300 mg kg^?1. By comparing their changes in molecular masses (ΔM), retention times and spectral patterns with those of the parent compound, nine metabolites were detected and identified in urine, and eight in plasma as well as four in brain. It is also indicated that the deglycosylation and oxidation reactions were the main metabolic pathways in the biotransformation of timosaponin BIII in vivo and the structures of the nine metabolites were identified and proposed to be timosaponin BII(M1), the hydroxylated metabolite of TBII(M2), the hydroxylated metabolites of TBIII(M3 and M4), deglycosylation and monooxygenation product of TBIII(M5), the deglycosylation product of TBII(M6), timosaponin AIII(M8), the isomers of timosaponin AIII(M7 and M9).     

In Vivo Metabolism Study of Timosaponin BIII in Rat Using HPLC-QTOF-MS/MS

Timosaponin BIII, as one of the steroid saponins isolated from Anemarrhena asphodeloides Bge., was proved to have many pharmacological activities in recent years and became a natural active compound with good development prospect. In the present study, a simple and rapid method using high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry was developed for the determination of the structures of timosaponin BIII and its metabolites in rats after administrating intragastrically at 300 mg kg⁻¹. By comparing their changes in molecular masses (ΔM), retention times and spectral patterns with those of the parent compound, nine metabolites were detected and identified in urine, and eight in plasma as well as four in brain. It is also indicated that the deglycosylation and oxidation reactions were the main metabolic pathways in the biotransformation of timosaponin BIII in vivo and the structures of the nine metabolites were identified and proposed to be timosaponin BII(M1), the hydroxylated metabolite of TBII(M2), the hydroxylated metabolites of TBIII(M3 and M4), deglycosylation and monooxygenation product of TBIII(M5), the deglycosylation product of TBII(M6), timosaponin AIII(M8), the isomers of timosaponin AIII(M7 and M9).

     

The Fate and Intermediary Metabolism of Soyasapogenol in the Rat

Research suggests that soyasaponins are poorly absorbed in the GI tract and that soyasaponin aglycones or soyasapogenols are absorbed faster and in greater amounts than the corresponding soyasaponins. Therefore, it is important to understand the bioavailability of these compounds for the potential development of functional foods containing their components. In this paper, to investigate the metabolic characteristics of soyasapogenols A and B, the pharmacokinetic parameters in rats were determined via oral and intravenous administration. The liver metabolites of soyasapogenols were identified using UPLC–/Q-TOF–MS/MS, and their metabolic pathways were also speculated. The results show that, after oral administration, there was a bimodal phenomenon in the absorption process. T_max was about 2 h, and soyasapogenol was completely metabolized 24 h later. The bioavailability of soyasapogenol was superior, reaching more than 60%. There were sixteen metabolites of soyasapogenol A and fifteen metabolites of soyasapogenol B detected in rat bile. Both phase I and II metabolic transformation types of soyasapogenols, including oxidation, dehydrogenation, hydrolysis, dehydration, deoxidization, phosphorylation, sulfation, glucoaldehyde acidification, and conjugation with cysteine, were identified. In addition, soyasapogenol A could be converted into soyasapogenols B and E in the metabolic process. These results suggest that it is feasible to use soyasapogenols as functional ingredients in nutraceuticals or food formulations.     

Fabrication and Biological Assessment of Antidiabetic α-Mangostin Loaded Nanosponges: In Vitro,In Vivo,and In Silico Studies

Type 2 diabetes mellitus has been a major health issue with increasing morbidity and mortality due to macrovascular and microvascular complications. The urgent need for improved methods to control hyperglycemic complications reiterates the development of innovative preventive and therapeutic treatment strategies. In this perspective, xanthone compounds in the pericarp of the mangosteen fruit, especially α-mangostin (MGN), have been recognized to restore damaged pancreatic β-cells for optimal insulin release. Therefore, taking advantage of the robust use of nanotechnology for targeted drug delivery, we herein report the preparation of MGN loaded nanosponges for anti-diabetic therapeutic applications. The nanosponges were prepared by quasi-emulsion solvent evaporation method. Physico-chemical characterization of formulated nanosponges with satisfactory outcomes was performed with Fourier transform infra-red (FTIR) spectroscopy, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Zeta potential, hydrodynamic diameter, entrapment efficiency, drug release properties, and stability studies at stress conditions were also tested. Molecular docking analysis revealed significant interactions of α-glucosidase and MGN in a protein-ligand complex. The maximum inhibition by nanosponges against α-glucosidase was observed to be 0.9352 ± 0.0856 µM, 3.11-fold higher than acarbose. In vivo studies were conducted on diabetic rats and plasma glucose levels were estimated by HPLC. Collectively, our findings suggest that MGN-loaded nanosponges may be beneficial in the treatment of diabetes since they prolong the antidiabetic response in plasma and improve patient compliance by slowly releasing MGN and requiring less frequent doses, respectively.     

大鼠尿液中壬基酚的代谢轮廓

运用代谢组学方法研究了壬基酚对大鼠尿液代谢的影响, 通过高效液相色谱-飞行时间质谱技术建立了大鼠尿样的代谢指纹图谱, 用主成分分析法分析给药组与对照组代谢物指纹图谱的差异, 通过t检验选取潜在的生物标志物及效应标志物, 并结合代谢物数据库检索对其进行鉴定. 结果表明, 壬基酚给药后, 尿液中含量变化显著的成分苯基葡萄糖苷酸、L-高半胱氨酸、3-硝基丙酸、肌酸酐、左旋肉碱及5-羟色胺等构成了大鼠尿液代谢的轮廓, 它们在生物体内的变化可能对生殖系统、免疫系统、神经系统及脂肪的代谢造成一定的影响, 从代谢的角度解释了环境雌激素壬基酚对生物体的危害, 为毒理学研究提供了依据.     

Analysis of illegal dyes in food by LC/TOF-MS

A sensitive and accurate methodology was developed for the analysis of seven illegal dyes (Sudan I, Sudan II, Sudan III, Sudan IV, Sudan Orange G, Sudan R and Para Red,) used as additives in food products, such as chilli powder and steak sauces. The analytical methodology consisted of solvent extraction with acetonitrile followed by liquid chromatography time-of-flight mass spectrometry detection. Accurate mass measurements were crucial in order to achieve a high degree of specificity for the target analytes in such complex samples. The dyes were effectively extracted from spice and sauce matrices achieving recoveries higher than 75%. Because of the excellent mass accuracy obtained for the target analytes (better than 2?ppm), no cleanup of the samples was required using this methodology, thus leading to a better precision and reproducibility of the results from the quantitative point of view. Calibration curves were linear and covered two orders of magnitude (from 0.01 to 1?mg?L^?1) for all the compounds studied with the exception of Para Red. A detailed study of matrix effects is also included in this work, showing a clear improvement when dilution of the extracts was carried out. Method detection limits were in the low mg?kg^?1 range, and the precision, calculated as the relative standard deviation, ranged from 5 to 15%. The methodology was successfully applied to market samples in a survey performed as part of a regional research programme organized by the Andalusian Health Service in Spain, and a positive confirmation for Sudan I was obtained in a chilli powder sample.     

Detecting and Identifying in vivo Metabolites of Brodimoprim via LC/ESI-MS with Data-dependent Scanning

The present article covers a simple approach to detect and subsequently identify in vivo metabolites of brodimoprim, using high performance liquid chromatography coupled to ion trap mass spectrometer（LC/ESI-MS）, which is based on a data-dependent acquisition of isotope ions and result verified by full scan mass spectrum. The distinguished advantage of data-dependent scan is rapidness because it requires minimum sample preparation, and all the necessary data can be obtained in one chromatographic run. In addition, it is highly sensitive and selective, allowing detection of trace metabolites even in the presence of complex biomatrix. As a result, four phase-Ⅰ（M1--M4） and four Phase-Ⅱ（M5--M8） metabolites of brodimoprim were identified in urine after the oral administration of hrodimoprim to Wistar rats. Their chemical structures were proposed based on the interpretation of their CID fragmentation characterizations and the metabolic pathway was exhibited in this article.     

Investigation of In Vitro and In Vivo Metabolism of α-Amanitin in Rats Using Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method

The purpose of this study is to investigate the difference of in vitro–in vivo correlation of α-amanitin from clearance perspectives as well as to explore the possibility of extra-hepatic metabolism of α-amanitin. First, a liquid chromatography-quadrupole-time-of-flight-mass spectrometric (LC-qTOF-MS) method for α-amanitin in rat plasma was developed and applied to evaluate the in vitro liver microsomal metabolic stability using rat and human liver microsomes and the pharmacokinetics of α-amanitin in rat. The predicted hepatic clearance of α-amanitin in rat liver microsomes was quite low (5.05 mL/min/kg), whereas its in vivo clearance in rat (14.0 mL/min/kg) was close to the borderline between low and moderate clearance. To find out the difference between in vitro and in vivo metabolism, in vitro and in vivo metabolite identification was also conducted. No significant metabolites were identified from the in vivo rat plasma and the major circulating entity in rat plasma was α-amanitin itself. No reactive metabolites such as GSH-adducts were detected either. A glucuronide metabolite was newly identified from the in vitro liver microsomes samples with a trace level. A semi-mass balance study was also conducted to understand the in vivo elimination pathway of α-amanitin and it showed that most α-amanitin was mainly eliminated in urine as intact which implies some unknown transporters in kidney might play a role in the elimination of α-amanitin in rat in vivo. Further studies with transporters in the kidney would be warranted to figure out the in vivo clearance mechanism of α-amanitin.     

An approach to identifying sequential metabolites of a typical phenylethanoid glycoside, echinacoside, based on liquid chromatography-ion trap-time of flight mass spectrometry analysis

Metabolite identification for the compounds that undergo multiple and sequential metabolism is still a great challenge. Echinacoside (ECH), a typical phenylethanoid glycoside, contains multiple unstable chemical bonds and high reactive functional groups which are susceptible to multiple pathways of degradation and metabolism, leading great difficulties for its metabolite identification. This study proposed a novel approach for rapidly identifying the complicated and unpredictable metabolites of ECH, based on the powerful liquid chromatography hybrid ion trap and time of flight mass spectrometry (LC/MS-IT-TOF) analysis. Four degradation products were rapidly identified via the “fragmentation-degradation” comparisons. Five phase I and phase II metabolites of the degradation products were rapidly characterized via the crossover mass differences comparisons of their quasi-molecular ions with the potential precursors. Four direct phase I and phase II metabolites of the parent compound were identified by the mass differences analysis of the molecular ions between metabolites and the parent compound. Multiple stages of fragmentation patterns were used to confirm the metabolites characterizations. This study provides a novel approach to characterizing the complicated metabolites, and would be widely applicable for the metabolite identification of natural products.     

In Vitro and In Vivo Trypanocidal Efficacy of Synthesized Nitrofurantoin Analogs

African trypanosomes cause diseases in humans and livestock. Human African trypanosomiasis is caused by Trypanosoma brucei rhodesiense and T. b. gambiense. Animal trypanosomoses have major effects on livestock production and the economy in developing countries, with disease management depending mainly on chemotherapy. Moreover, only few drugs are available and these have adverse effects on patients, are costly, show poor accessibility, and parasites develop drug resistance to them. Therefore, novel trypanocidal drugs are urgently needed. Here, the effects of synthesized nitrofurantoin analogs were evaluated against six species/strains of animal and human trypanosomes, and the treatment efficacy of the selected compounds was assessed in vivo. Analogs 11 and 12, containing 11- and 12-carbon aliphatic chains, respectively, showed the highest trypanocidal activity (IC₅₀ < 0.34 µM) and the lowest cytotoxicity (IC₅₀ > 246.02 µM) in vitro. Structure-activity relationship analysis suggested that the trypanocidal activity and cytotoxicity were related to the number of carbons in the aliphatic chain and electronegativity. In vivo experiments, involving oral treatment with nitrofurantoin, showed partial efficacy, whereas the selected analogs showed no treatment efficacy. These results indicate that nitrofurantoin analogs with high hydrophilicity are required for in vivo assessment to determine if they are promising leads for developing trypanocidal drugs.